Overview
Overview
Cell-free paracrine alternative to stem cell therapy; captures the FULL bioactive output of UCT-WJ-MSCs including both vesicular (exosomes) and soluble (proteins, cytokines, growth factors) secretory fractions
FOR RESEARCH USE AND INTERNATIONAL USE ONLY
| Product Configurations |
|---|
| 1 mL vial / 3 mL vial / 4 mL vial / 9 mL vial |
| Contains exosome/extracellular vesicle fraction |
| Contains the full spectrum of soluble proteins, cytokines, chemokines, growth factors, and lipid mediators secreted during optimized MSC culture |
| Protein characterization by LC-MS/MS confirms 400 identified proteins per batch |
Difference
What Distinguishes Secretomes from Exosomes?
While exosome products contain the membrane-enclosed vesicular fraction (miRNAs, mRNAs, proteins within lipid bilayer), secretomes capture the COMPLETE paracrine output: all exosomes PLUS all soluble proteins — including growth factors too large or hydrophilic for exosomal packaging. Key soluble components exclusive to secretomes include: full-length HGF, IGF-1, VEGF (higher concentration), IL-10, IL-6, TGF-β1, Wnt ligands, FGF-2, EGF, and 400+ additional proteins identified by proteomics. This broader molecular diversity makes secretomes particularly effective for systemic applications requiring multi-pathway engagement.
Components
Key Components
| Component Class | Examples & Functions |
|---|---|
| Exosome/EV Fraction (50B/dose) | miR-146a, miR-21, miR-29, BDNF, GDNF, VEGF mRNA — all exosome cargo |
| Immunomodulatory Cytokines | IL-10, TGF-β1, PGE2, IDO — systemic anti-inflammatory effects |
| Angiogenic Growth Factors | VEGF-A, Ang-1, FGF-2, PDGF-BB — vascularization and tissue repair |
| Trophic Growth Factors | HGF, IGF-1, EGF, NGF, GDNF — organ-specific regeneration |
| Anti-Fibrotic Factors | Decorin, miR-29, HGF, Follistatin — fibrosis suppression |
| Extracellular Matrix Components | Fibronectin, Laminin, Collagen fragments — matrix scaffold support |
| Wnt & BMP Modulators | Wnt3a, sFRP-1, BMP-4 antagonists — stem cell niche activation |
| Lipid Mediators | Prostaglandins, lysophospholipids — immunomodulatory lipid signaling |
Applications
Therapeutic Applications
- Neurological: Stroke, Parkinson's, Multiple Sclerosis, TBI, Neuropathy
- Autoimmune & Inflammatory: Rheumatoid Arthritis, Lupus, Crohn's, Psoriasis
- Metabolic & Cardiovascular: Type 2 Diabetes, Heart Failure, Peripheral Artery Disease
- Pulmonary & Renal: COPD, Pulmonary Fibrosis, CKD, AKI
- Musculoskeletal: Osteoarthritis, Sports Injuries, Intervertebral Disc Degeneration
- Dermatological: Wound Healing, Skin Rejuvenation, Alopecia
- Reproductive Wellness: Erectile Dysfunction, Vaginal Atrophy
- Anti-Aging & General Wellness: Systemic Inflammation Reduction, Immune Reset
Evidence
Clinical Evidence
A 2025 comprehensive review (PMC12344367) confirmed MSC-secretome-derived soluble factors (HGF, VEGF, IL-10, IGF-1) provide the primary mechanisms of MSC therapeutic efficacy across all tested organ systems — with paracrine signaling now recognized as the dominant therapeutic pathway over direct differentiation. The secretome therefore represents the most concentrated form of MSC therapeutic output in a cell-free format.
Proteomic characterization of UCT-WJ-MSC secretomes by LC-MS/MS reveals 400+ proteins including growth factors, cytokines, extracellular matrix components, proteases/inhibitors, and regulatory proteins. The richer protein diversity of secretomes vs exosomes alone has been confirmed in multiple comparative studies to produce broader therapeutic responses — particularly in systemic applications.
In knee OA models, intra-articular MSC secretome injection (NCT07157891 Phase I planned) is being formally investigated in combination with PRGF, building on established exosome efficacy data to test the full paracrine output. This trial demonstrates growing clinical recognition of secretome-based therapy.